Previous 10 | Next 10 |
—Early intervention in hospitalized patients could help prevent progression of disease— —EDP1815 has demonstrated favorable tolerability and anti-inflammatory activity in a prior clinical trial— —Data expected during 2H 2020— —Evelo Mana...
CAMBRIDGE, Mass., May 04, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Mo...
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...
CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Neil Graham,...
Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...
In a filing , Evelo Biosciences (NASDAQ: EVLO ) has disclosed the resignations of its chief financial officer and a boardmember. More news on: Evelo Biosciences, Inc., Healthcare stocks news, Read more ...
Point Roberts, WA and Delta, BC - February 28, 2020 (Investorideas.com Newswire) Investorideas.com , a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in biotech, retail, real estate, sports, food & beverage (rest...
CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 40 th Ann...
Gainers: Bellerophon Therapeutics (NASDAQ: BLPH ) +144% . More news on: Bellerophon Therapeutics, Inc., Brickell Biotech, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...
Evelo Biosciences, Inc. (EVLO) Q4 2019 Earnings Conference Call February 13, 2020, 08:30 ET Company Participants Jessica Cotrone - VP & Head, Communications Balkrishan Gill - President, CEO & Director Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific ...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...